Beximco claims to be the first to produce Remdesivir, not Eskayef | The Business Standard
Skip to main content
  • Latest
  • Economy
    • Banking
    • Stocks
    • Industry
    • Analysis
    • Bazaar
    • RMG
    • Corporates
    • Aviation
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • Subscribe
    • Epaper
    • GOVT. Ad
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
The Business Standard

Wednesday
July 09, 2025

Sign In
Subscribe
  • Latest
  • Economy
    • Banking
    • Stocks
    • Industry
    • Analysis
    • Bazaar
    • RMG
    • Corporates
    • Aviation
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • Subscribe
    • Epaper
    • GOVT. Ad
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
WEDNESDAY, JULY 09, 2025
Beximco claims to be the first to produce Remdesivir, not Eskayef

Pharma

TBS Report
09 May, 2020, 07:40 pm
Last modified: 09 May, 2020, 10:22 pm

Related News

  • One dies from COVID-19 in 24 hrs
  • Covid-19: Two more deaths, 7 new cases reported in 24hrs
  • Covid-19: One more death, 10 new cases reported in 24hrs
  • Three die from Covid-19 in 24 hrs
  • Five Covid-19 deaths reported in 24 hours, 36 new cases detected

Beximco claims to be the first to produce Remdesivir, not Eskayef

TBS Report
09 May, 2020, 07:40 pm
Last modified: 09 May, 2020, 10:22 pm
File Photo: Vials of investigational coronavirus disease (Covid-19) treatment drug remdesivir are capped at a Gilead Sciences facility in La Verne, California, US March 18, 2020. Picture taken March 18, 2020. Gilead Sciences Inc/Handout via Reuters
File Photo: Vials of investigational coronavirus disease (Covid-19) treatment drug remdesivir are capped at a Gilead Sciences facility in La Verne, California, US March 18, 2020. Picture taken March 18, 2020. Gilead Sciences Inc/Handout via Reuters

Beximco Pharmaceuticals Ltd claims that it is the first company in Bangladesh, not Eksayef, to produce the potential coronavirus drug Remdesivir.

The pharmaceutical company made the claim in a press note issued on Saturday.

Here is the full press note from Beximco.

The Business Standard Google News Keep updated, follow The Business Standard's Google news channel

"Beximco Pharmaceuticals Ltd has taken notice of the news published in the online version of Daily Star and Daily Prothom Alo on May 8, 2020, (subsequently in their print versions the next day)  titled "Eskayef first to produce Remdesivir in the country" and "করোনার চিকিৎসায় দেশে প্রথম রেমডেসিভির উৎপাদন করল এসকেএফ", wherein it is mentioned that the company initiated distributing preparations from Friday. This was also republished by other news outlets.

We believe the story items were factually incorrect.

We would like to clarify that Beximco Pharma not only was the first company in Bangladesh to produce this drug, but also the only company which has submitted final product samples to the drug regulatory authority, Directorate General of Drug Administration (DGDA), for testing and approval. After producing this generic drug and successfully conducting all necessary tests in house we submitted final product samples to DGDA on 7th May 2020, for testing and approval.

This is a mandatory legal requirement which must be complied with before any company can distribute any drug in Bangladesh or globally. Beximco Pharma refrained from announcing that it has produced the drug because it felt doing so without being validated by the regulatory body would have been irresponsible and unethical and would have misled the public.

We are releasing this press note in greater public interest to clarify the matter and dispel any confusion that may have been caused by the above-mentioned news items."

Corporates / Top News / Covid-19 in Bangladesh

Beximco / Eskayef / COVID-19 / Coronavirus / remdesivir

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • Bangladesh Bank Governor Ahsan H Mansur. TBS Sketch
    Several bank audit reports contain cooked up data: BB governor
  • Workers pack undergarments at the packing section of a garment factory in Ashulia, on the outskirts of Dhaka, Bangladesh, April 19, 2025. Photo: REUTERS/Fatima Tuj Johora
    After US tariffs, jobs hang by a thread in Bangladesh's garments sector
  • Global Islami Bank rectifies 2023 figures, reports major loss instead of profit
    Global Islami Bank rectifies 2023 figures, reports major loss instead of profit

MOST VIEWED

  • None saw it coming: What went wrong in Bangladesh’s tariff negotiation with US 
    None saw it coming: What went wrong in Bangladesh’s tariff negotiation with US 
  • File Photo: Rajib Dhar/TBS
    Bangladesh faces economic impact as US introduces 35% tariff on exports
  • Representational image. Photo: Collected
    Bangladesh reserves above $24b even after making $2b ACU payment 
  • Electric buses for capital: Tk2,500cr to be spent in 2 years
    Electric buses for capital: Tk2,500cr to be spent in 2 years
  • Representational image. Photo: TBS
    35% US tariff to be disastrous for Bangladesh's exports, say economists and exporters
  • Clashes took place between police and protesters in Sylhet on 2 August. Photo: TBS
    Hasina authorised deadly crackdown on protesters during 2024 July uprising, BBC verifies leaked audio

Related News

  • One dies from COVID-19 in 24 hrs
  • Covid-19: Two more deaths, 7 new cases reported in 24hrs
  • Covid-19: One more death, 10 new cases reported in 24hrs
  • Three die from Covid-19 in 24 hrs
  • Five Covid-19 deaths reported in 24 hours, 36 new cases detected

Features

Dr Mostafa Abid Khan. Sketch: TBS

Actual impact will depend on how US retailers respond: Mostafa Abid Khan

1d | Economy
Thousands gather to form Bangla Blockade in mass show of support. Photo: TBS

Rebranding rebellion: Why ‘Bangla Blockade’ struck a chord

1d | Panorama
The Mitsubishi Xpander is built with families in mind, ready to handle the daily carpool, grocery runs, weekend getaways, and everything in between. PHOTO: Akif Hamid

Now made-in-Bangladesh: 2025 Mitsubishi Xpander

2d | Wheels
Students of different institutions protest demanding the reinstatement of the 2018 circular cancelling quotas in recruitment in government jobs. Photo: Mehedi Hasan

5 July 2024: Students announce class boycott amid growing protests

4d | Panorama

More Videos from TBS

Not only Hasina but also Awami League should be tried: Mirza Fakhrul

Not only Hasina but also Awami League should be tried: Mirza Fakhrul

1h | TBS Today
Trump considering sanctions on Russia

Trump considering sanctions on Russia

2h | TBS World
Iran receives missile shipment from China

Iran receives missile shipment from China

4h | TBS World
Will JPA be able to survive in the political arena?

Will JPA be able to survive in the political arena?

17h | TBS Stories
EMAIL US
contact@tbsnews.net
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Advertisement
  • Privacy Policy
  • Comment Policy
Copyright © 2025
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net